JP2007520258A - 活性物質を経皮投与するためのデバイス - Google Patents
活性物質を経皮投与するためのデバイス Download PDFInfo
- Publication number
- JP2007520258A JP2007520258A JP2006538740A JP2006538740A JP2007520258A JP 2007520258 A JP2007520258 A JP 2007520258A JP 2006538740 A JP2006538740 A JP 2006538740A JP 2006538740 A JP2006538740 A JP 2006538740A JP 2007520258 A JP2007520258 A JP 2007520258A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- minimal
- active substance
- protrusion
- protrusions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 63
- 239000011159 matrix material Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 239000002998 adhesive polymer Substances 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000033001 locomotion Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 44
- 239000010410 layer Substances 0.000 description 24
- -1 polytetrafluoroethylene Polymers 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
これは、角質層の障壁性を回避しながら、活性物質含有液体の投与を可能にするが、多くの場合、活性物質を液体形態で提供することが可能ではない。例えば、活性物質の不十分な溶解性または活性物質溶液の不十分な安定性が、その理由である。加えて、これらの極微針を通して適用される液体が少量なため、適用される活性物質の量は非常に少ない(数マイクログラムの範囲)。
したがって、本発明のデバイスの極小突起部は、極小突起部を皮膚内に挿入するのに、その後の皮膚からの抜き取りよりも小さい力を必要とすることを特徴とする。
突起部の厚さは、好ましくは、5〜100μmの範囲、とりわけ10〜50μmの範囲である。針型突起部の場合、先端部の厚さは、好ましくは、1〜10μmであり、反対側の末端では好ましくは、5〜100μmである。
一般的に、デバイスの全ての極小突起部は、本質的に同じ形状である;しかしながら、本発明は、異なる形状の極小突起部の2種または3種以上が存在する、デバイスの態様をも含む。
好適なプラスチック材料の例は、単独または組み合わせでの、アクリロニトリル−スチレンコポリマー、ポリメチルメタクリレート、PVC、ポリテトラフルオロエチレン、ポリアミド、ポリウレタン、およびポリスチレンを含む。
好適な金属の例は、ステンレススチール、チタニウムおよびチタニウム合金、アルミニウムおよびアルミニウム合金、コバルトの合金、クロミウムおよびモリブデンを含む。
極小突起部は、当業者には既知の方法である、射出成形、圧縮成形、熱成形、深絞り、押し出し、エッチング技術などによりつくることができる。
前記ポリマーマトリックス、活性物質含有貯留層、または感圧性粘着層の製造のための基本材料として好適なものは、特に単独または組み合わせでの以下のポリマーである:ポリ(メタ)アクリレート、ポリイソブチレン、ポリテルペン、エチレン−ビニルアセテートコポリマー、合成ゴム、スチレン−イソプレン−スチレンブロックコポリマー、スチレン−ブタジエン−スチレンブロックコポリマー、ホットメルト粘着剤、ゴムと樹脂との混合物、シリコーン感圧性粘着剤、ポリビニルアセテート、ポリビニルピロリドン、ポリビニルアルコール、ポリエチレングリコール、セルロース誘導体(例えば、ヒドロキシプロピルメチルセルロース)。前記ポリマーに基づく、感圧性粘着製剤(formulation)は、原則的に当業者に既知である。さらに、ポリマーマトリックス、および活性物質貯留層はそれぞれ、とりわけ、軟化剤、乳化剤、吸収促進剤、粘着付与剤、可溶化剤、安定化剤、充填剤およびキャリア物質の群からの、1種または2種以上の既知の助剤を含有することができる。
本発明のデバイスは、一方では、安全で長持ちする皮膚への接着により特徴付けられ、他方では、別な方法では経皮投与に好適でない活性物質の経皮投与を可能にする。
極小突起部は、返し型の固定構造(5)を有する。極小突起部の横断面は丸く、固定構造(5)も同じである。
矢印の一つの方向に極小ラック(micro-rack)(10)を動かすことにより、極小ギア(11)が駆動される。ギアの車軸(12)の遠位(皮膚に面する)領域に、図2に示されるようならせん固定構造を備えることができる。
複数のギアラック(10)およびギア(11)を用いることにより、複数のらせん極小突起部(4、5)の一方向性の駆動を達成することができる。この場合、それぞれのラック(10)1個につき、2つまたは3つ以上のギア(11)を一緒に駆動することも可能である。
Claims (17)
- 背面層、およびそれに接続する活性物質含有貯留層を有する、活性物質を経皮投与するためのデバイスであって、皮膚に差し込むのに好適であり、および突起部を皮膚から抜き取るのをより困難とさせる構造を備えた複数の極小突起部を、デバイスの皮膚に接触する表面に有していることを特徴とする、前記デバイス。
- 極小突起部を皮膚へ挿入するために、後の皮膚からの抜き取りより小さい力が必要とされることを特徴とする、請求項1に記載のデバイス。
- 極小突起部が針状であることを特徴とする、請求項1または2に記載のデバイス。
- 複数の極小突起部を含み、その長手方向の外形が1個または2個以上のアンダーカットを有し、それにより前記構造が形成されることを特徴とする、請求項1〜3のいずれかに記載のデバイス。
- 複数の極小突起部を含み、ここで前記構造は返しとして構成され、前記極小突起部のそれぞれが1個または2個以上の返しを有することを特徴とする、請求項1〜3のいずれかに記載のデバイス。
- らせん状に構成され回転自在に配置された複数の極小突起部を含み、それにより、回転運動を加えた際に、皮膚への差し込みが容易となり、かつ皮膚内での固定がもたらされることを特徴とする、請求項1〜3のいずれかに記載のデバイス。
- 極小機械的アクチュエーターにより、回転駆動が達成されることを特徴とする、請求項6に記載のデバイス。
- 極小突起部、または少なくとも数個の極小突起部が、活性物質含有貯留層に固定されていることを特徴とする、請求項1〜7のいずれかに記載のデバイス。
- 極小突起部、または少なくとも数個の極小突起部が、背面層に接続していることを特徴とする、請求項1〜8のいずれかに記載のデバイス。
- 極小突起部、または少なくとも数個の極小突起部が、中空針として構成されることを特徴とする、請求項1〜9のいずれかに記載のデバイス。
- 好ましくは、極小突起部の面と同一の広がりを有するように配置される、粘着性ポリマーマトリックスを皮膚側に有することを特徴とする、請求項1〜10のいずれかに記載のデバイス。
- 極小突起部がポリマーマトリックス層の面から、平均300μm未満で突き出ていることを特徴とする、請求項11に記載のデバイス。
- 粘着性ポリマーマトリックスが、同時に活性物質貯留層を構成し、任意に1種または2種以上の助剤と組み合わせて、1種または2種以上の活性物質を含有することを特徴とする、請求項11または12に記載のデバイス。
- ペプチド、タンパク質、オリゴヌクレオチド、およびポリヌクレオチドの群から選択される、1種または2種以上の活性物質を含有することを特徴とする、請求項1〜13のいずれかに記載のデバイス。
- 遺伝子組み換え抗原に加え、バクテリア、ウイルス、バクテリアトキソイド、オリゴヌクレオチドおよびポリヌクレオチドを含む群から好ましくは選択される、1種または2種以上のワクチンを含有することを特徴とする、請求項1〜14のいずれかに記載のデバイス。
- 活性物質またはワクチンをヒトまたは動物の体へ経皮投与するための、請求項1〜15のいずれかに記載のデバイスの使用。
- 活性物質またはワクチンが、遺伝子組み換え抗原に加え、ペプチド、タンパク質、バクテリア、ウイルス、不活性化ウイルス、バクテリアトキソイド、オリゴヌクレオチド、およびポリヌクレオチドを含む群から選択されることを特徴とする、請求項16に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10353629A DE10353629A1 (de) | 2003-11-17 | 2003-11-17 | Vorrichtung zur transdermalen Verabreichung von Wirkstoffen |
DE10353629.9 | 2003-11-17 | ||
PCT/EP2004/012458 WO2005049128A1 (de) | 2003-11-17 | 2004-11-04 | Vorrichtung zur transdermalen verabreichung von wirkstoffen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007520258A true JP2007520258A (ja) | 2007-07-26 |
JP4763612B2 JP4763612B2 (ja) | 2011-08-31 |
Family
ID=34585179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006538740A Expired - Fee Related JP4763612B2 (ja) | 2003-11-17 | 2004-11-04 | 活性物質を経皮投与するためのデバイス |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070081977A1 (ja) |
EP (1) | EP1684846B1 (ja) |
JP (1) | JP4763612B2 (ja) |
CN (1) | CN101068589B (ja) |
AT (1) | ATE389432T1 (ja) |
CA (1) | CA2546688C (ja) |
DE (2) | DE10353629A1 (ja) |
ES (1) | ES2304628T3 (ja) |
PL (1) | PL1684846T3 (ja) |
PT (1) | PT1684846E (ja) |
WO (1) | WO2005049128A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006334991A (ja) * | 2005-06-03 | 2006-12-14 | Univ Kansai | 微細針の射出成形方法 |
DE102006028987A1 (de) * | 2006-06-24 | 2007-12-27 | Lts Lohmann Therapie-Systeme Ag | Ultraschallverstärktes transdermales therapeutisches System |
DE102009056746A1 (de) * | 2009-12-04 | 2011-06-09 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System für die Verabreichung von Peptiden |
JP2013517889A (ja) * | 2010-01-29 | 2013-05-20 | ユーバイオメッド インク. | マイクロニードル及びマイクロニードル装置 |
US9586044B2 (en) | 2010-04-28 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Method for increasing the permeability of an epithelial barrier |
JP5860453B2 (ja) | 2010-04-28 | 2016-02-16 | キンバリー クラーク ワールドワイド インコーポレイテッド | 表面にナノ構造体を含む複合マイクロニードルアレイ |
AU2015271878B2 (en) * | 2010-04-28 | 2017-05-11 | Sorrento Therapeutics, Inc. | Device for delivery of rheumatoid arthritis medication |
PT2563450T (pt) | 2010-04-28 | 2017-08-28 | Kimberly Clark Co | Dispositivo para entrega de medicação para a artrite reumatóide |
CN102985131B (zh) | 2010-04-28 | 2016-06-29 | 金伯利-克拉克环球有限公司 | 用于递送siRNA的医疗装置 |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
PL3542851T3 (pl) | 2011-10-27 | 2022-04-25 | Sorrento Therapeutics, Inc. | Wszczepialne urządzenia do dostarczania środków biologicznie czynnych |
EP3574950B1 (en) | 2011-10-27 | 2021-02-17 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
CN103203072B (zh) * | 2013-03-25 | 2015-05-20 | 清华大学 | 金属微针阵列柔性贴片、经皮给药器件及经皮给药贴片 |
ITMI20130586A1 (it) * | 2013-04-11 | 2014-10-12 | Azienda Ospedaliero Universitaria P Isana | Microago e matrice di microaghi per uso medicale, e processo di produzione di detta matrice |
CN105727438A (zh) * | 2016-04-18 | 2016-07-06 | 朱志飞 | 螺旋微针祛皱装置及祛皱方法 |
DE102017117784A1 (de) | 2017-08-04 | 2019-02-07 | Lts Lohmann Therapie-Systeme Ag | Applikatorsystem enthaltend ein Mikronadelarray aufweisend einen Wirkstoff für die Wundheilung |
DE102017118419A1 (de) | 2017-08-11 | 2019-02-14 | Lts Lohmann Therapie-Systeme Ag | Mikronadelarray aufweisend einen Farbumschlag-Indikator |
BR112020004670A2 (pt) * | 2017-09-12 | 2020-09-15 | Lts Lohmann Therapie-Systeme Ag | dispositivo de microagulhas iontoforético |
DE102017126501A1 (de) | 2017-11-10 | 2019-05-16 | Lts Lohmann Therapie-Systeme Ag | Mikronadelsystem zur Applikation eines Hepatitis-Impfstoffes |
JP2021506790A (ja) | 2017-12-14 | 2021-02-22 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 塩形態の有効成分を含むマイクロニードルアレイ |
WO2019136033A2 (en) * | 2018-01-02 | 2019-07-11 | Evonik Corporation | Microneedle delivery system with anchor |
US11690799B2 (en) | 2018-04-19 | 2023-07-04 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying interferon |
KR102658659B1 (ko) | 2018-04-19 | 2024-04-17 | 에르테에스 로만 테라피-시스테메 아게 | 인터페론 적용을 위한 마이크로니들 시스템 |
DE102019105694A1 (de) | 2019-03-06 | 2020-09-10 | Lts Lohmann Therapie-Systeme Ag | Mikronadelarray aufweisend ein wärmeerzeugendes Element |
WO2022115906A1 (en) * | 2020-12-04 | 2022-06-09 | Stefan Mazy | Minimally invasive skin sample collection apparatus |
DE102021118997A1 (de) | 2021-07-22 | 2023-01-26 | Lts Lohmann Therapie-Systeme Ag. | Mikronadelarray mit Antiseptika |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000512529A (ja) * | 1996-06-18 | 2000-09-26 | アルザ コーポレイション | 薬剤の経皮放出又はサンプリングを高めるための装置 |
JP2001087392A (ja) * | 1999-08-24 | 2001-04-03 | Biosense Inc | 心臓内細胞送達システムおよび方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6614673A (ja) * | 1966-10-18 | 1968-04-19 | ||
GB1315796A (en) * | 1972-01-29 | 1973-05-02 | Vinnitsky Med I Im Ni Pirogova | Device for intraosseous injection of liquid substrances |
US4164943A (en) * | 1977-09-30 | 1979-08-21 | Thoratec Laboratories Corporation | Catheter anchor |
US4890514A (en) * | 1986-06-27 | 1990-01-02 | The J. L. Wickham Co., Inc. | Rotary indexing mechanism |
US4908213A (en) * | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
US6048337A (en) * | 1992-01-07 | 2000-04-11 | Principal Ab | Transdermal perfusion of fluids |
US5562102A (en) * | 1994-11-21 | 1996-10-08 | Taylor; Thomas V. | Multiple biopsy device |
US5657516A (en) * | 1995-10-12 | 1997-08-19 | Minnesota Mining And Manufacturing Company | Dual structured fastener elements |
CN1204257A (zh) * | 1995-12-09 | 1999-01-06 | 罗曼治疗系统有限责任公司 | 用于皮肤的表面稳定药物制剂 |
US5730829A (en) * | 1996-03-26 | 1998-03-24 | The Goodyear Tire & Rubber Company | Two drum turret for tire assembly |
ATE302041T1 (de) * | 1997-12-11 | 2005-09-15 | Alza Corp | Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses |
DE69806963T2 (de) * | 1997-12-11 | 2002-11-21 | Alza Corp., Mountain View | Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
JP2002517300A (ja) * | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | 微小針デバイスおよび製造方法ならびにそれらの使用 |
CA2390252A1 (en) * | 1999-11-15 | 2001-05-25 | Velcro Industries B.V. | Skin attachment member |
EP1164404A1 (en) * | 2000-06-14 | 2001-12-19 | Corning Incorporated | An optical switch having an impact printer head actuator |
US6656147B1 (en) * | 2000-07-17 | 2003-12-02 | Becton, Dickinson And Company | Method and delivery device for the transdermal administration of a substance |
JP4659336B2 (ja) * | 2000-10-26 | 2011-03-30 | アルザ・コーポレーシヨン | 被覆された微細突出物を有する経皮的薬剤配達装置 |
US20040106904A1 (en) * | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
US20050137525A1 (en) * | 2003-06-04 | 2005-06-23 | Georgia Tech Research Corporation | Drilling microneedle device |
US8353861B2 (en) * | 2003-09-18 | 2013-01-15 | Texmac, Inc. | Applicator for applying functional substances into human skin |
-
2003
- 2003-11-17 DE DE10353629A patent/DE10353629A1/de not_active Withdrawn
-
2004
- 2004-11-04 AT AT04797585T patent/ATE389432T1/de not_active IP Right Cessation
- 2004-11-04 US US10/579,809 patent/US20070081977A1/en not_active Abandoned
- 2004-11-04 JP JP2006538740A patent/JP4763612B2/ja not_active Expired - Fee Related
- 2004-11-04 DE DE502004006613T patent/DE502004006613D1/de active Active
- 2004-11-04 WO PCT/EP2004/012458 patent/WO2005049128A1/de active IP Right Grant
- 2004-11-04 CA CA2546688A patent/CA2546688C/en not_active Expired - Fee Related
- 2004-11-04 PT PT04797585T patent/PT1684846E/pt unknown
- 2004-11-04 ES ES04797585T patent/ES2304628T3/es active Active
- 2004-11-04 EP EP04797585A patent/EP1684846B1/de not_active Not-in-force
- 2004-11-04 CN CN2004800338811A patent/CN101068589B/zh not_active Expired - Fee Related
- 2004-11-04 PL PL04797585T patent/PL1684846T3/pl unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000512529A (ja) * | 1996-06-18 | 2000-09-26 | アルザ コーポレイション | 薬剤の経皮放出又はサンプリングを高めるための装置 |
JP2001087392A (ja) * | 1999-08-24 | 2001-04-03 | Biosense Inc | 心臓内細胞送達システムおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
DE10353629A1 (de) | 2005-06-16 |
CA2546688C (en) | 2012-03-13 |
ES2304628T3 (es) | 2008-10-16 |
CN101068589B (zh) | 2010-05-12 |
CN101068589A (zh) | 2007-11-07 |
US20070081977A1 (en) | 2007-04-12 |
DE502004006613D1 (de) | 2008-04-30 |
PT1684846E (pt) | 2008-06-25 |
EP1684846A1 (de) | 2006-08-02 |
PL1684846T3 (pl) | 2008-08-29 |
WO2005049128A1 (de) | 2005-06-02 |
CA2546688A1 (en) | 2005-06-02 |
JP4763612B2 (ja) | 2011-08-31 |
EP1684846B1 (de) | 2008-03-19 |
ATE389432T1 (de) | 2008-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4763612B2 (ja) | 活性物質を経皮投与するためのデバイス | |
US10391290B2 (en) | Microneedle injection apparatus comprising a dual cover | |
JP5267910B2 (ja) | マイクロニードルアレイ | |
US7440798B2 (en) | Substance delivery system | |
JP5966156B2 (ja) | 剣山型マイクロニードルのアプリケータデバイス | |
US8506530B2 (en) | Microneedles to be placed in the skin for the transdermal application of pharmaceuticals | |
KR100993477B1 (ko) | 약물 송달 및 다른 용도를 위한 신속 용해형마이크로-퍼포레이터 | |
US6908448B2 (en) | Substance delivery device | |
Tiwary et al. | Innovations in transdermal drug delivery: formulations and techniques | |
Bernadete Riemma Pierre et al. | Microneedle-based drug delivery systems for transdermal route | |
WO2007116959A1 (ja) | マイクロニードルデバイスおよびマイクロニードル付き経皮薬物投与装置 | |
JP2005021677A (ja) | 経皮投薬用パッドベース、及び注射針 | |
JP2007075629A (ja) | 経皮的薬剤配達装置 | |
ES2908820T3 (es) | Matriz de microagujas con un principio activo en forma de sales | |
TW201400140A (zh) | 鑲嵌式經皮藥物釋放貼片及其製造方法 | |
TW200539907A (en) | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections | |
WO2017043627A1 (ja) | マイクロニードル製剤 | |
JP2020529269A (ja) | 創傷治癒のための活性成分を含むマイクロニードルアレイを備えるアプリケータシステム | |
WO2008134237A1 (en) | Skin penetrating touch fasteners | |
Sowmya et al. | Transdermal therapeutic systems—An overview | |
WO2024053625A1 (ja) | 局所適用システム | |
CA3223732A1 (en) | Microneedle array with antiseptics | |
Pierre et al. | 7. Microneedle technology for transdermal drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110517 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110609 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4763612 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |